EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gubra AS's Enterprise Value is €576.7 Mil.
Gubra AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €227.1 Mil. Therefore, Gubra AS's EV-to-FCF for today is 2.54.
The historical rank and industry rank for Gubra AS's EV-to-FCF or its related term are showing as below:
STU:PI3'
s EV-to-FCF Range Over the Past 10 Years
Min: -388.67 Med: -71.47 Max: 200.42
Current: 2.55
During the past 7 years, the highest EV-to-FCF of Gubra AS was 200.42. The lowest was -388.67. And the median was -71.47.
STU:PI3's EV-to-FCF is ranked better than 68.75% of 336
companies
in the Biotechnology industry
Industry Median: 14.885
vs STU:PI3: 2.55
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gubra AS's share price for today is €43.04.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gubra AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €13.767.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gubra AS EV-to-FCF Related Terms
Gubra AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Gubra AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gubra AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Gubra AS's EV-to-FCF falls into.
Gubra AS's current Enterprise Value is €576.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gubra AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €227.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (STU:PI3) has a EV-to-FCF of 2.54 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gubra AS and its competitors. According to the industry distribution chart, Gubra AS ranks #105 out of 336 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Gubra AS's EV-to-FCF too high?
Gubra AS's current EV-to-FCF is 2.54. The Biotechnology industry median EV-to-FCF is 14.89. Gubra AS's value of 2.54 is 82.9% below this industry median. Based on the distribution chart, Gubra AS ranks #105 out of 336 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gubra AS has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #105 out of 336 companies for EV-to-FCF. This puts Gubra AS in the upper half of its industry. The industry median EV-to-FCF is 14.89. Gubra AS's value of 2.54 is 82.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.89, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gubra AS's current EV-to-FCF of 2.54 is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gubra AS and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current EV-to-FCF is 2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (STU:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €379.79, compared to a current price of €43.04 — trading 88.7% below its estimated fair value. The current EV-to-FCF is 2.54 and 82.9% below the Biotechnology industry median of 14.89. Gubra AS's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Gubra AS (STU:PI3), the current EV-to-FCF is 2.54 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (STU:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €43.04 is trading 88.7% below its estimated GF Value™ of €379.79.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for STU:PI3:
EV-to-FCF: 2.54
GF Value™: €379.79 vs. price of €43.04 (88.7% below fair value)
Industry Position: 82.9% below the Biotechnology median (#105 of 336)
No single metric tells the full story. See the STU:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
60GF Score
Get the complete analysis for STU:PI3
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PI3 has been successfully added to your 
